stockrow
Saturday 7 November 2026
Export BMEA’s income statement to Excel — free account
Biomea Fusion, Inc.
BMEA Healthcare Biotechnology
- EPS
- +76.5%
- Free cash flow
- +47.8%
Quarter to June 2026, against a year earlier
0.56
0.03
−5.08%
Follow BMEA
Alert me
Biomea Fusion, Inc. (BMEA) P/E ratio
Biomea Fusion, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IBIO iBio, Inc. compare | n/m |
| BMEA Biomea Fusion, Inc. | n/m |
| SGMOQ Sangamo Therapeutics, Inc. compare | n/m |
| ATHE Alterity Therapeutics Limited - Sponsored ADR compare | n/m |
| LONA LeonaBio, Inc. compare | n/m |
| CRBU Caribou Biosciences, Inc. compare | n/m |
| GANX Gain Therapeutics, Inc. compare | n/m |
| SER Serina Therapeutics, Inc. compare | n/m |
| ATNM Actinium Pharmaceuticals, Inc. compare | 3.9× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)